Phase II trial of cancer vaccine MUC-1 [CVac] in patients with resectable triple-negative breast cancer.
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Cancer vaccine MUC-1 (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
- 25 Jun 2013 New trial record
- 24 Jun 2013 The trial protocol will be finalised and applications for regulatory and ethics committee approvals will be initiated in the coming months, according to a Prima Biomed media release.